View Older Stories View More Recent Stories

Sep 15, 2016 10:01PM Gilead Prices $5 Billion of Senior Unsecured Notes
Sep 6, 2016 01:00PM Gilead Sciences to Present at Three Upcoming Investor Conferences in September
Aug 23, 2016 09:01AM Gilead Sciences (GILD) Adds Cisco Systems' Kramer as Director
Aug 23, 2016 08:55AM Kelly A. Kramer Joins Gilead Sciences’ Board of Directors
Aug 22, 2016 11:50AM Gilead Sciences (GILD) Receives EC Marketing Approval for Truvada in HIV-1 Risk Reduction
Aug 22, 2016 11:49AM European Commission Grants Marketing Authorization for Gilead’s Once-Daily Truvada® For Reducing the Risk of Sexually Acquired HIV-1
Aug 19, 2016 08:31AM Portola Pharma (PTLA) Says IndexXa MAA Accepted for Review in Europe
Jul 25, 2016 04:10PM Gilead Sciences Announces Third Quarter 2016 Dividend
Jul 22, 2016 07:17AM European CHMP Adopts Positive Opinion on Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV
Jul 21, 2016 04:33PM Gilead Sciences (GILD) Announces Two Odefsey Phase 3b Studies Met Primary Objectives
Jul 21, 2016 04:30PM Gilead’s Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week Objective in Two Phase 3b Studies
Jul 18, 2016 05:00PM Gilead Sciences to Release Second Quarter 2016 Financial Results on Monday, July 25, 2016
Jul 8, 2016 09:02AM Ligand Pharma (LGND) Enters OmniAb Licensing Agreement with Gilead (GILD)
Jun 28, 2016 12:35PM Gilead Sciences (GILD) Receives FDA Approval for Epclusa as HCV Treatment in All Genotypes
Jun 28, 2016 10:25AM U.S. Food and Drug Administration Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C
Jun 23, 2016 07:54AM Gilead Sciences (GILD) Granted EC Marketing Approval for Odefsey STR
Jun 23, 2016 07:53AM European Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV
Jun 20, 2016 08:32AM Gilead Sciences (GILD) Presents Prelim. Data from Bictegravir Phase 1
Jun 20, 2016 08:30AM Gilead Presents Preliminary Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV
Jun 13, 2016 05:00PM Gilead Sciences to Present at the 36th Annual William Blair Growth Stock Conference on Tuesday, June 14
Jun 9, 2016 05:00PM Gilead Sciences to Present at the Jefferies 2016 Healthcare Conference on Friday, June 10
Jun 7, 2016 05:00PM Gilead Sciences to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8
May 27, 2016 07:30AM Gilead's (GILD) Epclusa Receives Positive CHMP Opinion for Treatment of All Genotypes of Chronic HCV
May 27, 2016 07:25AM European CHMP Adopts Positive Opinion for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C
May 24, 2016 04:31PM Gilead Sciences (GILD) Names Kevin Young CBE as COO
May 24, 2016 04:30PM Gilead Sciences Announces Appointment of Kevin Young CBE as Chief Operating Officer and Martin Silverstein, MD as Executive Vice President, Strategy
May 20, 2016 05:00PM Gilead Sciences to Present at the UBS Global Healthcare Conference on Monday, May 23
May 9, 2016 05:00PM Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 10
Apr 29, 2016 08:24AM Gilead (GILD) Announces CHMP Adopts Positive Opinion for TAF-Based Single Tablet Regimen Odefsey for Treatment of HIV
Apr 29, 2016 08:21AM European CHMP Adopts Positive Opinion for Gilead’s TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for Treatment of HIV
Apr 28, 2016 04:02PM Gilead Sciences Announces Second Quarter 2016 Dividend
Apr 25, 2016 07:11AM Gilead's (GILD) Descovy Granted EMA Marketing Authorization for Two Dosages
Apr 25, 2016 07:10AM European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV
Apr 21, 2016 05:00PM Gilead Sciences to Release First Quarter 2016 Financial Results on Thursday, April 28, 2016
Apr 18, 2016 06:29AM Gilead Sciences (GILD) Presents Data for Several HCV Inhibitor Phase 2, 3s; Includes Potential New Harvoni Indication
Apr 18, 2016 06:28AM Gilead Sciences (GILD) Announces Presentation of New Data for NASH, PSC Treatments
Apr 16, 2016 07:30AM Gilead Announces Multiple Scientific Presentations Demonstrating Broad Utility of Sofosbuvir-Based Hepatitis C Therapies
Apr 16, 2016 06:30AM Gilead Presents New Data Highlighting Progress in Liver Fibrosis
Apr 15, 2016 06:22AM Gilead Sciences (GILD) Offers Results from Two TAF Phase 3s; Both Studies Met Primary Endpoints
Apr 15, 2016 04:30AM Gilead Announces Full 48-Week Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection
Apr 4, 2016 02:57PM Gilead Sciences (GILD) Announces FDA Approval of Descovy as TAF-Based HIV Therapy
Apr 4, 2016 02:57PM U.S. Food and Drug Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide), Gilead’s Third TAF-Based HIV Therapy
Mar 31, 2016 06:54AM Gilead Sciences (GILD) Announces Submission of NDA for TAF as HBV Treatment to Japan's PMDA
Mar 31, 2016 02:02AM Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Tenofovir Alafenamide (TAF) for Patients with Chronic Hepatitis B Infection
Mar 10, 2016 05:00PM Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 15
Mar 4, 2016 06:00PM Gilead Sciences Announces Settlement Method for 1.625% Convertible Senior Notes Due 2016
Mar 4, 2016 04:00PM Gilead Sciences to Present at the Cowen & Company 36th Annual Health Care Conference on Monday, March 7
Mar 1, 2016 02:07PM Gilead Sciences (GILD) Announces FDA Approval of Odefsey as HIV-1 Treatment in Certain Patients
Mar 1, 2016 02:06PM U.S. Food and Drug Administration Approves Gilead’s Second TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection
Feb 26, 2016 07:52AM European CHMP Adopts Positive Opinion for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine/Tenofovir Alafenamide) for the Treatment of HIV
View More Recent Stories View Older Stories